F C Barone

Summary

Affiliation: SmithKline Beecham Pharmaceuticals
Country: USA

Publications

  1. ncbi Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia
    F C Barone
    SmithKline Beecham Pharmaceuticals, Department of Cardiovascular Pharmacology, King of Prussia, PA 19406, USA
    Med Res Rev 21:129-45. 2001
  2. ncbi Therapeutic potential of anti-inflammatory drugs in focal stroke
    F C Barone
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Expert Opin Investig Drugs 9:2281-306. 2000
  3. ncbi Carvedilol prevents severe hypertensive cardiomyopathy and remodeling
    F C Barone
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    J Hypertens 16:871-84. 1998
  4. ncbi SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia
    F C Barone
    Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    J Pharmacol Exp Ther 296:312-21. 2001
  5. ncbi Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats
    F C Barone
    Department of Cardiovascular Pharmacology, UW2521 709 Swedeland Road, P O Box 1539, King of Prussia, PA 19406, USA frank c
    Cardiovasc Res 50:525-37. 2001
  6. ncbi Interleukin-1 receptor and receptor antagonist gene expression after focal stroke in rats
    X Wang
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Stroke 28:155-61; discussion 161-2. 1997
  7. ncbi Ischemic preconditioning and brain tolerance: temporal histological and functional outcomes, protein synthesis requirement, and interleukin-1 receptor antagonist and early gene expression
    F C Barone
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA Frank
    Stroke 29:1937-50; discussion 1950-1. 1998
  8. ncbi SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia
    J J Legos
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, PO Box 1539, 709 Swedeland Road, King of Prussia, PA 19406, USA
    Brain Res 892:70-7. 2001
  9. ncbi Subtractive cloning identifies tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) increased gene expression following focal stroke
    X Wang
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Stroke 29:516-20. 1998
  10. ncbi Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size
    A M Romanic
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Stroke 29:1020-30. 1998

Detail Information

Publications23

  1. ncbi Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia
    F C Barone
    SmithKline Beecham Pharmaceuticals, Department of Cardiovascular Pharmacology, King of Prussia, PA 19406, USA
    Med Res Rev 21:129-45. 2001
    ....
  2. ncbi Therapeutic potential of anti-inflammatory drugs in focal stroke
    F C Barone
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Expert Opin Investig Drugs 9:2281-306. 2000
    ....
  3. ncbi Carvedilol prevents severe hypertensive cardiomyopathy and remodeling
    F C Barone
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    J Hypertens 16:871-84. 1998
    ..In previous studies, carvedilol has been demonstrated to confer significant cardiac protection in acute ischemic paradigms and reduction of left ventricle hypertrophy in spontaneously hypertensive rats...
  4. ncbi SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia
    F C Barone
    Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    J Pharmacol Exp Ther 296:312-21. 2001
    ....
  5. ncbi Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats
    F C Barone
    Department of Cardiovascular Pharmacology, UW2521 709 Swedeland Road, P O Box 1539, King of Prussia, PA 19406, USA frank c
    Cardiovasc Res 50:525-37. 2001
    ..In the present studies, eprosartan's ability to provide end-organ protection was evaluated in a model of cardiomyopathy and renal failure in stroke-prone rats (SP)...
  6. ncbi Interleukin-1 receptor and receptor antagonist gene expression after focal stroke in rats
    X Wang
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Stroke 28:155-61; discussion 161-2. 1997
    ..To hypothesize the involvement of the IL-1 system in ischemic injury, we examined other IL-1 components, including IL-1ra, IL-1RI, and IL-1RII for their mRNA expression after focal stroke...
  7. ncbi Ischemic preconditioning and brain tolerance: temporal histological and functional outcomes, protein synthesis requirement, and interleukin-1 receptor antagonist and early gene expression
    F C Barone
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA Frank
    Stroke 29:1937-50; discussion 1950-1. 1998
    ....
  8. ncbi SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia
    J J Legos
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, PO Box 1539, 709 Swedeland Road, King of Prussia, PA 19406, USA
    Brain Res 892:70-7. 2001
    ....
  9. ncbi Subtractive cloning identifies tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) increased gene expression following focal stroke
    X Wang
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Stroke 29:516-20. 1998
    ..To identify de novo expression of ischemia-induced genes, we applied subtractive cDNA library strategy to identify the genes that are selectively upregulated by focal stroke...
  10. ncbi Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size
    A M Romanic
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Stroke 29:1020-30. 1998
    ..The present study was designed to investigate the effects of MMP expression after stroke...
  11. ncbi Inflammatory gene expression in cerebral ischemia and trauma. Potential new therapeutic targets
    G Z Feuerstein
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    Ann N Y Acad Sci 825:179-93. 1997
    ....
  12. ncbi Application of real-time polymerase chain reaction to quantitate induced expression of interleukin-1beta mRNA in ischemic brain tolerance
    X Wang
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA
    J Neurosci Res 59:238-46. 2000
    ..These data suggest that the significant but low levels of IL-1beta induction after PC may contribute to ischemic brain tolerance...
  13. ncbi Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban
    J A Erhardt
    Department of Cardiovascular Pharmacology, GlaxoSmithKline, King of Prussia, PA 19406, USA
    Thromb Res 103:143-8. 2001
  14. ncbi Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction
    R N Willette
    Department of Cardiovascular Pharmacology, GlaxoSmithKline, King of Prussia, Pennsylvania 19406 0939, USA
    J Cardiovasc Pharmacol 38:606-17. 2001
    ..Mixed ETA /ETB receptor antagonism improves cardiac performance and attenuates ventricular remodeling and premature mortality in an aggressive hypertension model...
  15. ncbi Identification and molecular characterization of rat CXCR3: receptor expression and interferon-inducible protein-10 binding are increased in focal stroke
    X Wang
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA, USA
    Mol Pharmacol 57:1190-8. 2000
    ..In addition, the cloning of rat CXCR3 provides an important tool for the investigation of the pathophysiological role of CXCR3 in other rodent disease models...
  16. ncbi SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes
    A M Badger
    Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    J Immunol 161:467-73. 1998
    ..The iNOS mRNA levels were consistent with NO levels in 24-h cell culture supernatants of the IL-1-stimulated bovine chondrocytes used to obtain the RNA...
  17. ncbi Discovery of adrenomedullin in rat ischemic cortex and evidence for its role in exacerbating focal brain ischemic damage
    X Wang
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Proc Natl Acad Sci U S A 92:11480-4. 1995
    ....
  18. ncbi Selective antagonism of endothelin-A-receptors improves outcome in both head trauma and focal stroke in rat
    F C Barone
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmacology, King of Prussia, Pennsylvannia 19406, USA
    J Cardiovasc Pharmacol 36:S357-61. 2000
    ..These data indicate that ET plays a significant role in the pathophysiology of CHI, and that selectively targeting ET(A)-receptors similarly in both CHI and stroke might be a therapeutic opportunity...
  19. ncbi Endothelin levels increase in rat focal and global ischemia
    F C Barone
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406
    J Cereb Blood Flow Metab 14:337-42. 1994
    ....
  20. ncbi Demonstration of increased endothelial-leukocyte adhesion molecule-1 mRNA expression in rat ischemic cortex
    X Wang
    Department of Cardiovascular Pharmacology, Smith Kline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Stroke 26:1665-8; discussion 1668-9. 1995
    ..The aim of the present study was to evaluate whether endothelial-leukocyte adhesion molecule-1 (ELAM-1 or E-selectin) mRNA expression is upregulated in focal brain ischemia...
  21. ncbi Cholecystokinin stimulates neuronal receptors to produce contraction of the canine colon
    F C Barone
    Department of Pharmacology, Smith Kline and French Laboratories, King of Prussia, PA 19406
    Life Sci 44:533-42. 1989
    ..Proglumide and CBZ-CCK27-32-amide are effective CCK receptor antagonists at these colonic neuronal receptors...
  22. ncbi Molecular cloning and expression of the rat monocyte chemotactic protein-3 gene: a possible role in stroke
    X Wang
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Brain Res Mol Brain Res 71:304-12. 1999
    ..Molecular cloning of rat MCP-3 should provide a valuable tool, as demonstrated in the present work, for the investigation of MCP-3 expression and function in rat disease models...
  23. ncbi Modulation of LPS-induced pulmonary neutrophil infiltration and cytokine production by the selective PPARbeta/delta ligand GW0742
    Z Haskova
    Biopharmaceutical Center for Excellence in Drug Discovery, GlaxoSmithKline, King of Prussia, PA, USA
    Inflamm Res 57:314-21. 2008
    ..To define the anti-inflammatory effects of PPARbeta/delta activation by use of the selective PPARbeta/delta ligand (GW0742) in a model of lipopolysaccharide (LPS)-induced pulmonary inflammation...